Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke
Purpose This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence. Methods The evaluable study cohort (n = 2748) was derived from the data...
Gespeichert in:
Veröffentlicht in: | Pharmacoepidemiology and drug safety 2017-02, Vol.26 (2), p.201-207 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 207 |
---|---|
container_issue | 2 |
container_start_page | 201 |
container_title | Pharmacoepidemiology and drug safety |
container_volume | 26 |
creator | Wawruch, Martin Zatko, Dusan Wimmer, Gejza Luha, Jan Hricak, Vasil Murin, Jan Kukumberg, Peter Tesar, Tomas Hloska, Adam Shah, Rashmi |
description | Purpose
This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence.
Methods
The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence.
Results
During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent.
Conclusions
Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/pds.4148 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1868316003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1847892642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3498-6ca3dcaf8289c49df010625e90c0446f78ed4e44763e096d61cceb808b07e983</originalsourceid><addsrcrecordid>eNqNkb9u2zAQxokiReMmBfIEAYEsXeSQIkWRY-H8aQEDMZDsAk2dajo0pZI0DG8ZO-YZ-ySh4jRDp053uO9335H4EDqjZEoJKS-HNk455fIDmlCiVEGrqj4a-4oVshLqGH2OcU1I1hT_hI7LWrGKVnSCfi90suDTn6fnAE4naLFZ6aBNgmBjsiZiHWNv7Ku0s2mFfe8zPUCIGQBv4DCOKTt5nFYQ9LDHuQXXQnB7PBxORNz1zvU7639i7bGNZgUba_Ji6B_hFH3stIvw5a2eoIeb64fZ92J-d_tj9m1eGMaVLITRrDW6k6VUhqu2I5SIsgJFDOFcdLWElgPntWBAlGgFNQaWksglqUFJdoK-HmyH0P_aQkzNJj8EnNMe-m1sqBSSUUEI-w-U11KVgpcZvfgHXffb4PM_RkOmhJLlaHj-Rm2XG2ibIdiNDvvmbxoZKA7AzjrYv-uUNGPKTU65GVNuFlf3Y2UvHPedlA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1863969823</pqid></control><display><type>article</type><title>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Wawruch, Martin ; Zatko, Dusan ; Wimmer, Gejza ; Luha, Jan ; Hricak, Vasil ; Murin, Jan ; Kukumberg, Peter ; Tesar, Tomas ; Hloska, Adam ; Shah, Rashmi</creator><creatorcontrib>Wawruch, Martin ; Zatko, Dusan ; Wimmer, Gejza ; Luha, Jan ; Hricak, Vasil ; Murin, Jan ; Kukumberg, Peter ; Tesar, Tomas ; Hloska, Adam ; Shah, Rashmi</creatorcontrib><description>Purpose
This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence.
Methods
The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence.
Results
During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent.
Conclusions
Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.4148</identifier><identifier>PMID: 27935151</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Aged ; Aged, 80 and over ; anxiety disorders ; Anxiety Disorders - epidemiology ; Brain Ischemia - drug therapy ; Cohort Studies ; Dementia ; Diabetes ; diabetes mellitus ; Female ; Follow-Up Studies ; Health risk assessment ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; hypercholesterolemia ; Male ; Medication Adherence - statistics & numerical data ; Patients ; persistence ; Polypharmacy ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Slovakia ; statin ; Statins ; Stroke ; Stroke - drug therapy</subject><ispartof>Pharmacoepidemiology and drug safety, 2017-02, Vol.26 (2), p.201-207</ispartof><rights>Copyright © 2016 John Wiley & Sons, Ltd.</rights><rights>Copyright © 2017 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3498-6ca3dcaf8289c49df010625e90c0446f78ed4e44763e096d61cceb808b07e983</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.4148$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.4148$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27935151$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wawruch, Martin</creatorcontrib><creatorcontrib>Zatko, Dusan</creatorcontrib><creatorcontrib>Wimmer, Gejza</creatorcontrib><creatorcontrib>Luha, Jan</creatorcontrib><creatorcontrib>Hricak, Vasil</creatorcontrib><creatorcontrib>Murin, Jan</creatorcontrib><creatorcontrib>Kukumberg, Peter</creatorcontrib><creatorcontrib>Tesar, Tomas</creatorcontrib><creatorcontrib>Hloska, Adam</creatorcontrib><creatorcontrib>Shah, Rashmi</creatorcontrib><title>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidemiol Drug Saf</addtitle><description>Purpose
This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence.
Methods
The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence.
Results
During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent.
Conclusions
Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>anxiety disorders</subject><subject>Anxiety Disorders - epidemiology</subject><subject>Brain Ischemia - drug therapy</subject><subject>Cohort Studies</subject><subject>Dementia</subject><subject>Diabetes</subject><subject>diabetes mellitus</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>hypercholesterolemia</subject><subject>Male</subject><subject>Medication Adherence - statistics & numerical data</subject><subject>Patients</subject><subject>persistence</subject><subject>Polypharmacy</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Slovakia</subject><subject>statin</subject><subject>Statins</subject><subject>Stroke</subject><subject>Stroke - drug therapy</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkb9u2zAQxokiReMmBfIEAYEsXeSQIkWRY-H8aQEDMZDsAk2dajo0pZI0DG8ZO-YZ-ySh4jRDp053uO9335H4EDqjZEoJKS-HNk455fIDmlCiVEGrqj4a-4oVshLqGH2OcU1I1hT_hI7LWrGKVnSCfi90suDTn6fnAE4naLFZ6aBNgmBjsiZiHWNv7Ku0s2mFfe8zPUCIGQBv4DCOKTt5nFYQ9LDHuQXXQnB7PBxORNz1zvU7639i7bGNZgUba_Ji6B_hFH3stIvw5a2eoIeb64fZ92J-d_tj9m1eGMaVLITRrDW6k6VUhqu2I5SIsgJFDOFcdLWElgPntWBAlGgFNQaWksglqUFJdoK-HmyH0P_aQkzNJj8EnNMe-m1sqBSSUUEI-w-U11KVgpcZvfgHXffb4PM_RkOmhJLlaHj-Rm2XG2ibIdiNDvvmbxoZKA7AzjrYv-uUNGPKTU65GVNuFlf3Y2UvHPedlA</recordid><startdate>201702</startdate><enddate>201702</enddate><creator>Wawruch, Martin</creator><creator>Zatko, Dusan</creator><creator>Wimmer, Gejza</creator><creator>Luha, Jan</creator><creator>Hricak, Vasil</creator><creator>Murin, Jan</creator><creator>Kukumberg, Peter</creator><creator>Tesar, Tomas</creator><creator>Hloska, Adam</creator><creator>Shah, Rashmi</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>7U7</scope><scope>C1K</scope></search><sort><creationdate>201702</creationdate><title>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</title><author>Wawruch, Martin ; Zatko, Dusan ; Wimmer, Gejza ; Luha, Jan ; Hricak, Vasil ; Murin, Jan ; Kukumberg, Peter ; Tesar, Tomas ; Hloska, Adam ; Shah, Rashmi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3498-6ca3dcaf8289c49df010625e90c0446f78ed4e44763e096d61cceb808b07e983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>anxiety disorders</topic><topic>Anxiety Disorders - epidemiology</topic><topic>Brain Ischemia - drug therapy</topic><topic>Cohort Studies</topic><topic>Dementia</topic><topic>Diabetes</topic><topic>diabetes mellitus</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>hypercholesterolemia</topic><topic>Male</topic><topic>Medication Adherence - statistics & numerical data</topic><topic>Patients</topic><topic>persistence</topic><topic>Polypharmacy</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Slovakia</topic><topic>statin</topic><topic>Statins</topic><topic>Stroke</topic><topic>Stroke - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wawruch, Martin</creatorcontrib><creatorcontrib>Zatko, Dusan</creatorcontrib><creatorcontrib>Wimmer, Gejza</creatorcontrib><creatorcontrib>Luha, Jan</creatorcontrib><creatorcontrib>Hricak, Vasil</creatorcontrib><creatorcontrib>Murin, Jan</creatorcontrib><creatorcontrib>Kukumberg, Peter</creatorcontrib><creatorcontrib>Tesar, Tomas</creatorcontrib><creatorcontrib>Hloska, Adam</creatorcontrib><creatorcontrib>Shah, Rashmi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wawruch, Martin</au><au>Zatko, Dusan</au><au>Wimmer, Gejza</au><au>Luha, Jan</au><au>Hricak, Vasil</au><au>Murin, Jan</au><au>Kukumberg, Peter</au><au>Tesar, Tomas</au><au>Hloska, Adam</au><au>Shah, Rashmi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidemiol Drug Saf</addtitle><date>2017-02</date><risdate>2017</risdate><volume>26</volume><issue>2</issue><spage>201</spage><epage>207</epage><pages>201-207</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
This study was aimed at evaluating the extent of non‐persistence with statin therapy in elderly patients after an ischemic stroke and identifying patient‐related characteristics that are risk factors for non‐persistence.
Methods
The evaluable study cohort (n = 2748) was derived from the database of the largest health insurance provider in the Slovak Republic. Patients aged ≥65 years who were initiated on statin therapy following the diagnosis of an ischemic stroke during one full year (1 January 2010 to 31 December 2010) constituted this cohort. Each patient was followed for a period of 3 years from the date of the first statin prescription. Patients with a continuous treatment gap of 6 months without statin prescription were designated as non‐persistent. The Cox proportional hazard model was applied to determine patient‐associated characteristics that influenced the likelihood of non‐persistence.
Results
During the 3‐year follow‐up period, 39.7% of patients in the study cohort became non‐persistent. Factors associated with decreased probability of a patient becoming non‐persistent were age ≥75 years (hazard ratio (HR) 0.75), polypharmacy (concurrent use of ≥6 drugs) (HR 0.79), diabetes mellitus (HR 0.80), dementia (HR 0.81) and hypercholesterolemia (HR 0.50). On the other hand, the presence of anxiety disorders (HR 1.33) predicted an increased likelihood of a patient being non‐persistent.
Conclusions
Our findings suggest that patients aged ≥75 years or those with the presence of diabetes mellitus, dementia, hypercholesterolemia or polypharmacy were likely to be persistent with statin therapy, whereas those with anxiety disorders may need greater assistance with persistence of statin therapy. Copyright © 2016 John Wiley & Sons, Ltd.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>27935151</pmid><doi>10.1002/pds.4148</doi><tpages>7</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1053-8569 |
ispartof | Pharmacoepidemiology and drug safety, 2017-02, Vol.26 (2), p.201-207 |
issn | 1053-8569 1099-1557 |
language | eng |
recordid | cdi_proquest_miscellaneous_1868316003 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Aged Aged, 80 and over anxiety disorders Anxiety Disorders - epidemiology Brain Ischemia - drug therapy Cohort Studies Dementia Diabetes diabetes mellitus Female Follow-Up Studies Health risk assessment Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage hypercholesterolemia Male Medication Adherence - statistics & numerical data Patients persistence Polypharmacy Proportional Hazards Models Retrospective Studies Risk Factors Slovakia statin Statins Stroke Stroke - drug therapy |
title | Patient‐related characteristics associated with non‐persistence with statin therapy in elderly patients following an ischemic stroke |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T17%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient%E2%80%90related%20characteristics%20associated%20with%20non%E2%80%90persistence%20with%20statin%20therapy%20in%20elderly%20patients%20following%20an%20ischemic%20stroke&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Wawruch,%20Martin&rft.date=2017-02&rft.volume=26&rft.issue=2&rft.spage=201&rft.epage=207&rft.pages=201-207&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.4148&rft_dat=%3Cproquest_pubme%3E1847892642%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1863969823&rft_id=info:pmid/27935151&rfr_iscdi=true |